Ennaid Therapeutics, a Georgia-based pharmaceutical company owned by Darnisha Harrison, is seeking FDA approval for an antiviral drug they believe could help those that have tested positive for COVID-19
⠀
Darnisha (one of the first African-American women to start a major drug company) says her scientists created a drug called ENU200 that could “treat as much as 80 percent of asymptomatic, mild to moderate COVID-19 infections.”
⠀
Darnisha: “Our science strongly suggests that ENU200, a repurposed drug with a well-established clinical and safety profile, has the potential to be a broad solution to address the COVID-19 pandemic. Unlike other COVID-19 drugs in development, which must be administered via injection or intravenously under the care of a physician, ENU200 can be administered orally, thus enabling in-home treatment for COVID-19 infections.”
⠀
ENU200 has been previously approved by the U.S. Food and Drug Administration, but for a different purpose. “We anticipate the clinical trials could start within 90 days. The clinical trial itself could take a month. We feel quite optimistic that in the 120-day window when our clinical material would be ready, we could have a drug that could be safe and effective at treating COVID-19.”
Add Comment